Cs-131 Prostate Brachytherapy and Treatment Plan Parameters
Authors: Sutlief S and Wallner K
- Home
- About
- Brachytherapy
Patient Information
Clinician Information
Cesium 131 Products
- Theranostics
- Newsroom
- Investor Center
- Contact us
The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.
Authors
Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V.
- Published in journal:
International Journal of Radiation Oncology Biology Physics
February 1, 2003
Dr. Armpilia reports on and derives equations for the formal mathematics of Biologic Effective Dose. According to the mathematical models that take into account variables related to the ability of certain cancers to grow aggressively even while being irradiated, Dr. Armpilia concludes that Cs-131 will successfully treat a wider range of possible cancer types than other brachytherapy isotopes.
Related posts
Dosimetric Evaluation of Permanent Prostate Brachytherapy Using Cs-131 Sources
Authors: Steven Kurtzman, M.D
Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy
Authors: J.S. Musmacher, R.T. Byrnes, M. Ghaly, K. Satchwill, L. Rumpf
Company
Brachytherapy
Theranostics
Company
©2023. All rights reserved. Terms & Privacy | Privacy Policy